APTNOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

ADAPTIN BIO, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$6.27+0.00 (0.00%)

Close on Aug 19, 2026

Market cap: $55.48M
P/E (TTM): –
Dividend yield: –

ADAPTIN BIO, INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash & Equivalents	0.46	0.03	0.00	0.00
Cash & Short-Term Investments	0.46	0.03	0.00	0.00
Prepaid Expenses & Other	0.16	0.01	–	–
Total Current Assets	0.62	0.05	0.00	0.00
Total Assets	0.62	0.24	0.00	0.00
Accounts Payable	1.51	1.36	0.00	0.01
Accrued Expenses	0.60	1.05	–	–
Total Current Liabilities	2.11	4.34	0.11	0.03
Total Liabilities	2.11	4.34	0.11	0.03
Common Stock	0.00	0.00	0.00	0.00
Additional Paid-In Capital	7.80	0.02	–	–
Retained Earnings	-9.29	-4.12	-0.11	-0.03
Shareholders' Equity	-1.49	-4.10	-0.98	-0.03
Total Equity	-1.49	-4.10	-0.98	-0.03
Total Liabilities & Equity	0.62	0.24	0.00	0.00
Shares Outstanding(shares)	8.66	3.25	5.00	5.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 184.9%

Financial strength

Current ratio: 0.37
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 25.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –